GBM Program

Evidence: Public Summary

What we can share publicly about our research

Information presented represents historical observations and preclinical research. Results may not be generalizable and do not predict future clinical outcomes.

Preclinical Research

Our preclinical program includes both in vitro (cell culture) and in vivo (animal model) studies examining the effects of GLA on glioma cells. Laboratory findings have informed our understanding of potential mechanisms and supported advancement toward IND-enabling studies.

  • Cell culture studies examining effects on glioma cell lines
  • Animal model studies with local GLA administration
  • Mechanistic studies exploring lipid peroxidation pathways
  • Comparative studies with normal brain tissue
Historical Clinical Observations

Historical observations in patients were conducted prior to current regulatory frameworks. These limited, non-randomized observations documented individual patient experiences but do not meet modern clinical trial standards.

  • Historical case observations documented over time
  • Limited patient numbers with varying conditions
  • Non-randomized, open-label design
  • Variable individual responses observed
Safety/Toxicology

Safety evaluation is a critical component of our IND-enabling program. Preclinical toxicology studies are designed to characterize the safety profile of local GLA administration.

  • GLP toxicology studies planned/ongoing
  • Local tissue effects assessment
  • Systemic exposure evaluation
  • Safety monitoring protocols in development

What may be available upon request

For qualified parties under appropriate agreements

Protocol synopses and development plansUpon Request
Preclinical study reports and summariesUpon Request
Investigator background materialsUpon Request
Manufacturing and stability overviewUpon Request
Regulatory strategy summariesUpon Request

Important Notice: This website describes investigational research. Our programs (ARKA-101, SURYA-101) are not approved for clinical use. Content is educational and for partnership discussions, not medical advice.